BIOHD

STUDY OF BIOMARKERS THAT PREDICT THE EVOLUTION OF HUNTINGTON’S DISEASE

Unknown

ABOUT

SPONSOR

Assistance Publique - Hôpitaux de Paris

PARTICIPANTS

1800

BIOHD is aiming to identify biomarkers in the blood, imaging, and through psychological tests. This is done in order to be able to better predict the progression of Huntington’s disease (HD) – before symptoms are visible.

What is a biomarker? It is a measurable indicator of a disease or condition. It can for instance be a level of something in your blood or hormon levels. Biomarkers are often measured and evaluated to examine normal biological processes – like measuring the level of hemoglobin in your blood or your blood pressure. In reference to research on Huntingtons disease, a biomarker is an indicator of disease progression. 

Estimated Study Completion Date: January 2021

Ages Eligible for Study:

18 Years and older (Adult, Older Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria

Gene Positive (people who carry the Huntington’s disease gene):

  • Voluntary patients symptomatic or asymptomatic
  • Patient with a number of CAG ≥36)
  • Patient who know his/her/their genetic status
  • Age greater than 18 years or equal to 18 years
  • Patient who provided written informed consent

Control Group:

  • Voluntary controls with no family history of huntington’s disease
  • Control with a number of CAG <36
  • Age greater than 18 years or equal to 18 years
  • Control who provided written informed consent

Exclusion Criteria

  • Deterioration of the protocol preventing the understanding of the protocol

COUNTRIES

FRANCE

TRIAL SITE:
Hôpital Henri Mondor

Address: Creteil, France, 94010

CONTACT
Bachoud-Lévi Anne-Catherine
Tel: (0)1 49 81 23 01 ext +33
bachoud@gmail.com